KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables - Other: 2012-2025

Historic Receivables - Other for Supernus Pharmaceuticals (SUPN) over the last 2 years, with Sep 2025 value amounting to $6.3 million.

  • Supernus Pharmaceuticals' Receivables - Other was N/A to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $4.0 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Receivables - Other stood at $6.3 million, which was up 16.67% from $5.4 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Receivables - Other's 5-year high stood at $6.3 million during Q3 2025, with a 5-year trough of $4.0 million in Q4 2024.
  • Over the past 2 years, Supernus Pharmaceuticals' median Receivables - Other value was $5.4 million (recorded in 2025), while the average stood at $5.2 million.